Innoviva, Inc. (INVA)
Pharmaceutical Preparations · Healthcare · $1.7B
Intrinsic Value (Consensus)
$64.20
Current Price
$22.61
Margin of Safety
+183.9%
183.9% Below Intrinsic Value
Value: $64
Price: $23
Valuation Model Estimates
Current Price: $22.61
DCF (Discounted Cash Flow)
$124.40
Graham Number
$34.35
Earnings Power Value
$32.04
Relative Value (P/E)
$66.00
Dividend Discount Model
Not applicable
—
Consensus Value
$64.20
Model Assumptions
Discount Rate
10.3%
Growth Rate
20.0%
Terminal Growth
2.5%
Risk-Free Rate
4.3%
Discount rate derived from CAPM (risk-free rate + beta × market risk premium). Growth rate based on trailing earnings growth, capped at 20%.
Health Score
B
72
Profitability
12/25
Strength
19/25
Valuation
22/25
Growth
19/25
Financial Health Signals
Strong earnings growth (20% YoY)
High free cash flow yield (11.7%) — generating lots of cash relative to price
Key Financials
- EPS (TTM)
- $3.30
- EPS (Forward)
- $3.96
- Book Value
- $15.89
- P/E Ratio
- 20.0
- Forward P/E
- 16.7
- PEG Ratio
- —
- ROE
- 0.4%
- Debt/Equity
- 64%
- Revenue Growth
- 14.7%
- Earnings Growth
- 20.0%
- Dividend Yield
- N/A
- Beta
- 1.00
Similar Stocks (Healthcare)
ABEOAbeona Therapeutics ...
$37.06+300%
ABUSArbutus Biopharma Co...
$18.93+300%
ADVBAdvanced Biomed Inc....
$26.66+300%
AGENAgenus Inc.
$20.19+300%
ATRAAtara Biotherapeutic...
$41.43+300%
Data last updated: 2026-06-16
Source: Yahoo Finance